News

Bloomberg Law: Lost Work, ER Visits Urged in Drug Panel’s Migraine Analysis

02.28.20

Lost work days and time spent in emergency rooms should have weighed more heavily in an analysis of migraine medicines by an influential advisory board, advocates said. The Institute for Clinical and Economic Review, a nonprofit that analyzes whether a drug’s outcome for patients justifies its price tag, can sway insurers’ decisions on drug coverage. It recently determined that Allergan’s Ubrelvy, Eli Lilly’s Reyvow, and rimegepant—a Biohaven drug still being considered for approval by the…

Politico: ICER Revises Migraine Report, But Advocacy Groups Still Not Satisfied

02.28.20

The Institute for Clinical and Economic Review revised its previous assessment of two new migraine drugs, determining that they meet its long-term cost-effectiveness thresholds — after previously ruling the cost of the medicines was too high. The final evidence report concluded that Allergan’s Ubrelvy, which costs $4,896 a year, and Biohaven’s rimegepant meet the cost-effectiveness threshold.

Inside Health Policy: Advocacy Groups Push ICER To Reevaluate Migraine Drug Analysis

02.28.20

Policy and patient advocacy groups are calling on the Institute for Clinical and Economic Review to rerun its analysis on the cost-effectiveness of three drugs to treat acute migraines, using ICER’s updated framework that considers societal factors. The advocacy groups expect the cost-effectiveness rating of the three drugs would increase further using that framework.  

We Need to Look Beyond Drugs in Value Assessment

12.03.19

In the United States, we are engaged in the challenging but important conversation about how to assess the value of pharmaceuticals. While efforts to improve the frameworks for drug value assessment are emerging, we are missing an important opportunity if we continue to focus all value assessment energy on just drugs. To be truly relevant to sustainable value-based health care decision-making, we must advance methods and tools that can effectively support comparative assessment of a broader array…

ICER’s concern for patients: Where’s the beef?

10.09.19

The Institute for Clinical and Economic Review, commonly known as ICER, wants everyone to believe that it cares about patients and that its value assessments of new drugs and treatments are intended to help them. How do we know that? It’s become the organization’s central talking point as it makes the rounds in advance of finalizing its revised Value Assessment Framework for 2020, which describes the methodology the organization will use in its assessments beginning next year.…

Discrimination has no place in American prescription drug coverage

08.06.19

If someone is older, sicker or more disabled, should less value be placed on treating them? Most Americans would be repulsed by the very question. However, one organization is using questionable methodology to determine whether medical treatments are worth it or not for the people most desperately in need. The Institute for Clinical and Economic Review issues reports about what medications are and are not worthy of being covered by insurance. Unfortunately, ICER relies on arbitrary and unscientific…

Discrimination has no place in American prescription drug coverage

08.06.19

If someone is older, sicker or more disabled, should less value be placed on treating them? Most Americans would be repulsed by the very question. However, one organization is using questionable methodology to determine whether medical treatments are worth it or not for the people most desperately in need. The Institute for Clinical and Economic Review issues reports about what medications are and are not worthy of being covered by insurance. Unfortunately, ICER relies on arbitrary and unscientific methodology to…

Value Our Health: Stop Discriminatory Value Assessments

07.08.19

Millions of Americans are living with chronic illnesses and disabilities. In generations past, we did not live well or long with these conditions. Today, scientific advancement has ushered in more innovative therapies and technologies than ever before. Societal evolution has led to policies that have made navigating the world as someone living with one or more of these conditions progressively better. Cancer patients, for example, are living longer than ever before. They have more options…